A5011233983- Colorectal Cancer Treatments and Studies
- Hepatitis C virus research
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Liver Disease Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Cervical Cancer and HPV Research
- Esophageal Cancer Research and Treatment
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Surgical Treatments
- Viral-associated cancers and disorders
- Advanced Breast Cancer Therapies
- Cancer Mechanisms and Therapy
- Radiopharmaceutical Chemistry and Applications
- Hedgehog Signaling Pathway Studies
- Bone health and treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Inflammatory Biomarkers in Disease Prognosis
- Lymphoma Diagnosis and Treatment
Icahn School of Medicine at Mount Sinai
2023-2025
Mount Sinai Medical Center
2004-2024
Mount Sinai Hospital
2024
Northwell Health
2020-2023
Montefiore Medical Center
2013-2022
Albert Einstein College of Medicine
2011-2022
Lenox Hill Hospital
2020-2022
Hofstra University
2022
Feinstein Institute for Medical Research
2020
Montefiore Einstein Comprehensive Cancer Center
2019
Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in > 70% pancreatic cancers (PCs). We investigated the impact vismodegib, SHH antagonist, plus gemcitabine (GV) or placebo (GP) a multicenter phase Ib/randomized II trial and preclinical PC models.
Previous communication has reported significant improvement in overall survival (OS) when using doxorubicin plus sorafenib the treatment of advanced hepatocellular cancer (HCC).To determine if added to therapy improves OS, with stratification for locally and metastatic disease.This unblinded randomized phase 3 clinical trial was led by Alliance collaboration Eastern Cooperative Oncology Group-American College Radiology Imaging Network, Canadian Cancer Trials Group, Southwest Group. It...
192 Background: An exploratory analysis of a randomized phase II study in HCC comparing doxorubicin (D) alone to plus sorafenib (D+S) showed significant improvement overall survival favoring D+S (JAMA, 2011). The results appeared promising compared the historic outcomes seen pivotal (S) trials. CALGB 80802 was designed determine if improved S alone. Methods: Patients with histologically proven advanced HCC, no prior systemic therapy and Child-Pugh A were receive D 60 mg/m 2 every 21 days 400...
4000 Background: E/GEJ adenocarcinoma has a high mortality rate despite curative intent therapy. Although the use of immune checkpoint inhibition (ICI) in combination with chemotherapy metastatic setting and as adjuvant monotherapy both confer survival benefits, its role neoadjuvant chemoradiation or other ICIs remains unclear. Here we report impact nivo on pCR pts receiving part EA2174 clinical trial. Methods: Pts localized T1N1-3M0 T2-3N0-2M0 an ECOG PS 0-1 deemed surgical candidates for...
Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after definitive chemoradiation (CRT), associated with anogenital human papilloma virus, and often appears in HIV infection. Because cetuximab enhances effect radiation therapy virus–associated oropharyngeal SCC, we hypothesized that adding to CRT would reduce LRF SCCAC. Methods Forty-five patients stage I III SCCAC infection received CRT: 45 54 Gy primary tumor regional lymph...
Antibodies to programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may perturb human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) by reversing HIV latency and/or boosting HIV-specific immunity, leading clearance of infected cells. We tested this hypothesis in a clinical trial anti-PD-1 alone or combination with anti-CTLA-4 people living (PLWH) cancer.This was substudy the AIDS Malignancy Consortium 095 Study. ART-suppressed...
4500 Background: Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2). The primary objective of RTOG 1010 was to determine if trastuzumab increases disease-free survival (DFS) when combined with trimodality treatment for patients HER2 overexpressing esophageal adenocarcinoma. Methods: This open label, randomized phase III trial included newly diagnosed stage T1N1-2, T2-3N0-2 adenocarcinoma the esophagus involving mid, distal, or esophagogastric...
PURPOSE: To develop a combination of pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA) and docetaxel (Taxotere; Aventis Pharmaceutical, Parsipanny, NJ) that can be safely used for the treatment advanced breast cancer. PATIENTS AND METHODS: Forty-one patients with locally (n = 10) or metastatic 31) cancer received Doxil (30-, 40-, 45-mg/m 2 intravenous [IV] infusion over 30 to 60 minutes), followed 1 hour later by (60 75 mg/m IV hour) in cohorts three six patients....
4012 Background: Sonic Hh (SHh), the ligand for pathway, is over-expressed in >80% of PC. V had activity preclinical murine PC models leading to increased tumor perfusion, enhanced delivery G, and an improvement survival. Methods: We conducted a placebo-controlled, phase IB/randomized II trial GV or GP. Eligible pts, KPS 80-100, untreated metastatic PC, completed adjuvant therapy > 6 months (mo) prior. Primary endpoint: progression-free survival (PFS). Correlatives: serial SHh serum...
Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable alterations in most patients, clinical impact as part of routine management across all cancers the community remains unknown. Methods: we conducted a retrospective study patients that underwent CGP cancer from January 2013 June 2017 at an academic community-based NCI-designated center. was done addition...
4011 Background: The HH pathway is overexpressed in gastroesophageal (GE) tumors. Pre-clinically, inhibitors have demonstrated a reduction GE tumor growth, cell motility and invasiveness. V, an oral small-molecule antagonist of the Hh pathway, has previously been safely combined with FOLFOX chemotherapy. Methods: Pts untreated metastatic or locally advanced gastric GEJ adenocarcinoma were randomized 1:1, stratified by institution disease status (with w/o distant mets) to (ox 85 mg/m 2 , LV...
4003 Background: An exploratory analysis of a randomized phase II study in HCC comparing doxorubicin (D) alone to plus sorafenib (D+S) showed significant improvement overall survival favoring D+S (JAMA, 2011). The results appeared promising compared the historic outcomes seen pivotal (S) trials. CALGB 80802 was designed determine if improved S alone. Methods: Patients with histologically proven advanced HCC, no prior systemic therapy and Child-Pugh A were receive D 60 mg/m2 every 21 days 400...
PURPOSE Circulating tumor DNA (ctDNA) is an emerging tool in the evaluation of GI cancers. Challenges remain defining its utility and role as a primary end point therapeutic trials. The National Cancer Institute (NCI) ctDNA working group was created to evaluate current data provide guidance on inclusion cancer METHODS NCI steering committee assigned four task force members serve co-chairs for group. Co-chairs identified experts within each disease form panel that convened review...
There is recent interest in treating locally advanced rectal cancer (LARC) patients with total neoadjuvant therapy (TNT). However, whether TNT associated improved overall survival (OS) remains unknown. This study compares outcomes following and chemoradiation (nCRT) LARC, clinically defined cT3/4 or node positive disease, using the National Cancer Database.LARC diagnosed between 2004-2015 were included. was as multi-agent chemotherapy given at least 2 months before RT followed by...
Although immunotherapy has emerged as a therapeutic strategy for many cancers, there are limited studies establishing the safety and efficacy in people living with HIV (PLWH) cancer.